Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis

Breast Cancer Res Treat. 2016 May;157(1):191-2. doi: 10.1007/s10549-016-3798-8. Epub 2016 Apr 22.

Authors

P Lavaud¹, B Rousseau², Z Ajgal³, J Arrondeau³, O Huillard³, J Alexandre³, A Hulin⁴, F Goldwasser³

Affiliations

¹ Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France. pernelle.lavaud@gmail.com.
² Department of Medical Oncology, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil University, Paris, France.
³ Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
⁴ Department of Pharmacology, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil University, Paris, France.

PMID: 27106482
DOI: 10.1007/s10549-016-3798-8

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / blood
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary
Breast Neoplasms / pathology*
Diarrhea / chemically induced
Female
Humans
Lapatinib
Liver Neoplasms / drug therapy
Liver Neoplasms / secondary
Magnetic Resonance Imaging
Meningeal Carcinomatosis / diagnostic imaging
Meningeal Carcinomatosis / drug therapy*
Meningeal Carcinomatosis / secondary
Quinazolines / administration & dosage
Quinazolines / adverse effects
Quinazolines / blood
Quinazolines / therapeutic use*
Receptor, ErbB-2 / metabolism
Trastuzumab / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Quinazolines
Lapatinib
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab